← Back to Clinical Trials
Recruiting NCT05013944

NCT05013944 AnovaOS Network Powered Patient Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05013944
Status Recruiting
Phase
Sponsor Anova Enterprises, Inc
Condition Infectious Disease
Study Type OBSERVATIONAL
Enrollment 100,000 participants
Start Date 2021-09-01
Primary Completion 2025-08-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
All Conditions
Infectious Disease Neoplasms Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89) Endocrine, Nutritional and Metabolic Diseases (E00-E89) Mental and Behavioural Disorders Diseases of the Nervous System Diseases of the Eye and Adnexa Diseases of the Ear and Mastoid Process Diseases of the Circulatory System Diseases of the Respiratory System Diseases of the Digestive System Diseases of the Skin and Subcutaneous Tissue Diseases of the Musculoskeletal System and Connective Tissue Diseases of the Genitourinary System Pregnancy, Childbirth and the Puerperium Certain Conditions Originating in the Perinatal Period Congenital Malformations, Deformations and Chromosomal Abnormalities (Q00-Q99) Symptoms, Signs and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified Injury, Poisoning and Certain Other Consequences of External Causes External Causes of Morbidity and Mortality Factors Influencing Health Status and Contact With Health Services

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100,000 participants in total. It began in 2021-09-01 with a primary completion date of 2025-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this study is the development, implementation and management of a registry of patient data that captures clinically meaningful, real-world, data on the diagnosis, nature, course of infection, treatment(s) and outcomes in patients with complex disease globally.

Eligibility Criteria

Inclusion Criteria: * 18 years old or older; * Confirmed positive diagnosis of disease, condition or disorder. This will be self-reported or reported by the patient's provider, advocacy group or other patient representative; * Laboratory or other independent means of confirmation is not required but may be confirmed in clinical trials; * Able to understand and willing to sign the informed consent document; or whose legal representative has given consent to participate in the research per state and Federal requirements; * Willing and able to complete the registry questions or have the instrument(s) completed by an informed proxy; * Anticipated additional follow up with the registry once per year. Exclusion Criteria: * Subjects who do not meet the inclusion criteria for the study; * Subjects who are unable to understand the protocol or unable to provide legally effective informed consent

Contact & Investigator

Central Contact

Christopher Beardmore

✉ chris@anovaevidence.com

📞 +1 (224) 218-2408

Principal Investigator

Martin Walsh

STUDY DIRECTOR

Anova Enterprises, Inc

Frequently Asked Questions

Who can join the NCT05013944 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Infectious Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05013944 currently recruiting?

Yes, NCT05013944 is actively recruiting participants. Contact the research team at chris@anovaevidence.com for enrollment information.

Where is the NCT05013944 trial being conducted?

This trial is being conducted at Arlington Heights, United States.

Who is sponsoring the NCT05013944 clinical trial?

NCT05013944 is sponsored by Anova Enterprises, Inc. The principal investigator is Martin Walsh at Anova Enterprises, Inc. The trial plans to enroll 100,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology